A man diagnosed with terminal prostate cancer at age 48 says his cancer becomes “undetectable” years later after receiving a newer treatment approach that combines three therapies at once. Both outlets report that Kevin Mortimer was told his prognosis was poor and that he later achieved remission following the “triple attack” or “triplet” therapy.
The coverage describes triplet therapy as using three different treatments concurrently to target the cancer more effectively. The Daily Mail presents Mortimer as a strong responder, while The Independent focuses on the longer-term outcome—his cancer being undetectable three years after the terminal diagnosis.
While the articles highlight an individual case and frame the treatment as promising for men with prostate cancer, the reporting centers on Mortimer’s experience rather than presenting broader clinical trial results or population-level outcomes. The common thread across both sources is that triplet therapy is credited for sustaining an undetectable state after an initial terminal diagnosis.
